

ALL. B

Decreto Rettore Università di Roma "La Sapienza" D.R. n. 1828/2018 del 12/07/2018

Diletta Di Mitri Curriculum Vitae

Date 27/08/2018

Part I – General Information

Full Name	Diletta Di Mitri
Citizenship	Italian
E-mail	diletta.dimitri@pec.it
Spoken Languages	Italian (native speaker), English (fluent), German (beginner)

Part II – Education

Type	Year	Institution	Notes (Degree, Experience,...)
University graduation	2004	Università Alma Mater Studiorum di Bologna	Medical Biotechnology
Pre-graduate training	2003-2004	Università Alma Mater Studiorum Bologna, Department of Hematology	Master thesis
PhD	2008	Università degli studi di Roma Tor Vergata	Neuroscience

Part III – Appointments

Start	End	Institution	Position
2017	Until now	Humanitas Clinical and Research Center	Group leader/PI
2012	2017	Institute for Oncology Research (IOR), Bellinzona (Switzerland)	Senior post-doctoral fellow
2011	2012	IRCSS Santa Lucia Foundation, Rome	Post-doctoral fellow
2009	2011	University College London (UCL), London (UK)	Post-doctoral fellow

Part V – Fellowships, Awards and Honors, Society memberships

Fellowships

2010-2012	FISM (Italian Multiple Sclerosis Foundation) Senior Fellowship
2012-2014	TRAIN Oncology Marie Curie Co-fund fellowship

Awards

2017	Gerry Scotti Award per la ricerca sul cancro
2015	Pfizer research price 2015
2015	Best publication under 35 years, Switzerland
2014	What's up young talent awards (Campidoglio, Rome)
2014	Price for the best oral presentation (NIBIT 2014)
2011	Price for the best oral presentation (AINI XXI, 2011)
2008	Price for the best poster presentation (WIRM II, 2008)

Society memberships

2014 Ad hoc reviewer for the Journal of Immunology

Editorial board

2005 – 2012 Member of the AINI (Italian Neuroimmunology Association)

Part VI - Funding Information [grants as PI-principal investigator or I-investigator]

Year	Title	Program	Grant value
2018-2021	Young researcher GR, PI	Ricerca finalizzata 2016, Ministero della Salute	411.750 euro
2018-2023	AIRC Starting grant, PI	AIRC foundation, Starting grant 2016	750.000 euro

Part VII – Research Activities

Keywords	Brief Description
Tumor immunology	The objective of my research projects is a better understanding of the complex interplay between the cancer and its immune microenvironment. Main goal is the identification of novel biological processes candidate for therapeutic interventions aimed at re-programming the immune infiltrate against the tumor.
Prostate cancer	
Metastasis	
Innate immunity	
Pten	

Part VIII – Summary of Scientific Achievements

Product type	Number	Data Base	Start	End
Papers [international]	20	Scopus	2007	2018
Books [scientific]	1 chapter	Pro-senescence therapy for cancer: Time for the clinic	2015	-

Total Impact factor	218.479
Total Citations	1230
Average Citations per Product	61.5
Hirsch (H) index	12

Summary of Scientific Achievements (last 10 years, 2008-2018)

Product type	Number	Data Base	Start	End
Papers [international]	19	Scopus	2008	2018
Books [scientific]	1 chapter	Pro-senescence therapy for cancer: Time for the clinic	2015	-

Total Impact factor	205.315
Total Citations	600
Average Citations per Product	31,579
Hirsch (H) index	11

Summary of Scientific Achievements (last 5 years, 2013-2018)

Product type	Number	Data Base	Start	End
Papers [international]	11	Scopus	2013	2018
Books [scientific]	1 chapter	Pro-senescence therapy for cancer: Time for the clinic	2015	-

Total Impact factor	173,441
Total Citations	250
Average Citations per Product	22,727
Hirsch (H) index	7

Part IX- Conferences

- "World Immune Regulation Meeting II (WIRM 2008)", DAVOS, poster presentation
- "XVIII AINI congress", Napoli (Italia), 08-11/10/2008, oral presentation
- "ISNI (International school of Neuroimmunology)" Fort Worth (Texas), 26-30/10/2008, oral presentation
- "XXI AINI congress" Pollenzo (Italia), 22-25/09/2011, oral presentation

- "XXII AINI congress", Catania (Italia), 26-29/09/2012, oral presentation
- " XII NIBIT Meeting - Cancer BioImmunotherapy", Siena, Italia, 09-11/10/2014, oral presentation
- "6th international conference on Tumor-host interaction and Angiogenesis", Ascona, Switzerland, 17-20/05/2015, oral presentation
- "ISREC-SCCL 2016: Horizons of cancer biology and therapy", 07-10/09/2016, poster presentation
- "ESMO" Madrid, Spain 09-12/09/2017, poster oral presentation
- "Milan Meets Immunology 2018, Milano, Italia, Chair in the session "Immunity in cancer and other diseases", 26-02-2018.

Part X– Selected Publications

List of the publications selected for the evaluation. For each publication report title, authors, reference data, journal IF (if applicable), citations, press/media release (if any).

1. Arianna Calcinotto, Clarissa Spataro, Diletta Di Mitri, Elena Zagato, Veronica Gil, Mateus Crespo, Semini Sumanasuriya, Gaston De Bernardis, Marco Losa, Emiliano Pasquini, Adam Sharp, David Dolling, Alberto Briganti, Antonio Esposito, Simon Barry, Johann De Bono & Andrea Alimonti. Nature, accepted. IL23 secreted by myeloid-derived suppressor cells confers castration resistance in prostate cancer. Cit: 1. IF: 40.137
2. Chen J, Guccini I Di Mitri D, Brina D, Revandkar A, Sarti M, Pasquini E, Alajati A, Pinton S, Losa M, Civenni G, Catapano CV, Sgrignani J, Cavalli A, D'Antuono R, Asara JM, Morandi A, Chiarugi P, Crotti S, Agostini M, Montopoli M, Masgras I, Rasola A, Garcia-Escudero R, Delaleu N, Rinaldi A, Bertoni F, Bono J, Carracedo A, Alimonti A. Nat Genet. 2018 Feb;50(2):219-228. doi: 10.1038/s41588-017-0026-3. Epub 2018 Jan 15. Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer. Cit: 5. IF: 27.959
- 3: Di Mitri D, Alimonti A. Non-Cell-Autonomous Regulation of Cellular Senescence in Cancer. Trends Cell Biol. 2016 Mar;26(3):215-26. doi: 10.1016/j.tcb.2015.10.005. Epub 2015 Nov 9. Review. PubMed PMID: 26564316. Cit: 19. IF: 13.527
- 4: Di Mitri D, Sambucci M, Loiarro M, De Bardi M, Volpe E, Cencioni MT, Gasperini C, Centonze D, Sette C, Akbar AN, Borsellino G, Battistini L. The p38 mitogen-activated protein kinase cascade modulates T helper type 17 differentiation and functionality in multiple sclerosis. Immunology. 2015 Oct;146(2):251-63. doi: 10.1111/imm.12497. Epub 2015 Jul 6. PubMed PMID: 26095162; PubMed Central PMCID: PMC4582966. Cit: 10. IF: 3.358
- 5: Di Mitri D, Toso A, Alimonti A. Molecular Pathways: Targeting Tumor-Infiltrating Myeloid-Derived Suppressor Cells for Cancer Therapy. Clin Cancer Res. 2015 Jul 15;21(14):3108-12. doi: 10.1158/1078-0432.CCR-14-2261. Epub 2015 May 12. PubMed PMID: 25967145. Cit: 10. IF: 9.619
- 6: Di Mitri D, Toso A, Alimonti A. Tumor-infiltrating myeloid cells drive senescence evasion and chemoresistance in tumors. Oncoimmunology. 2015 Jun 3;4(9):e988473. eCollection 2015 Sep. PubMed PMID: 26405613; PubMed Central PMCID: PMC4570142. Cit: 1. IF: 7.719
- 7: Kalathur M, Toso A, Chen J, Revandkar A, Danzer-Baltzer C, Guccini I, Alajati A, Sarti M, Pinton S, Brambilla L, Di Mitri D, Carbone G, Garcia-Escudero R, Padova A, Magnoni L, Tarditi A, Maccari L, Malusa F, Kalathur RK, A Pinna L, Cozza G, Ruzzene M, Delaleu N, Catapano CV, Frew IJ, Alimonti A. A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours. Nat Commun. 2015 Jun 18;6:7227. doi: 10.1038/ncomms8227. PubMed PMID: 26085373. Cit: 12. IF: 12.124

- 8: Toso A, Di Mitri D, Alimonti A. Enhancing chemotherapy efficacy by reprogramming the senescence-associated secretory phenotype of prostate tumors: A way to reactivate the antitumor immunity. *Oncoimmunology*. 2015 Jan 22;4(3):e994380. eCollection 2015 Mar. PubMed PMID: 25949917; PubMed Central PMCID: PMC4404842. Cit: 6. IF: 7.719
- 9: Toso A, Revandkar A, Di Mitri D, Guccini I, Proietti M, Sarti M, Pinton S, Zhang J, Kalathur M, Civenni G, Jarrossay D, Montani E, Marini C, Garcia-Escudero R, Scanziani E, Grassi F, Pandolfi PP, Catapano CV, Alimonti A. Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity. *Cell Rep*. 2014 Oct 9;9(1):75-89. doi: 10.1016/j.celrep.2014.08.044. Epub 2014 Sep 25. PubMed PMID: 25263564. Cit: 78. IF: 8.282
- 10: Di Mitri D, Toso A, Chen JJ, Sarti M, Pinton S, Jost TR, D'Antuono R, Montani E, Garcia-Escudero R, Guccini I, Da Silva-Alvarez S, Collado M, Eisenberger M, Zhang Z, Catapano C, Grassi F, Alimonti A. Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer. *Nature*. 2014 Nov 6;515(7525):134-7. doi: 10.1038/nature13638. Epub 2014 Aug 24. PubMed PMID: 25156255. Cit: 93. IF: 40.137
- 11: Camperio C, Muscolini M, Volpe E, Di Mitri D, Mechelli R, Buscarinu MC, Ruggieri S, Piccolella E, Salvetti M, Gasperini C, Battistini L, Tuosto L. CD28 ligation in the absence of TCR stimulation up-regulates IL-17A and pro-inflammatory cytokines in relapsing-remitting multiple sclerosis T lymphocytes. *Immunol Lett*. 2014 Mar-Apr;158(1-2):134-42. doi: 10.1016/j.imlet.2013.12.020. Epub 2014 Jan 8. PubMed PMID: 24412596. Cit: 15. IF: 2.86
- 12: Di Mitri D, Azevedo RI, Henson SM, Libri V, Riddell NE, Macaulay R, Kipling D, Soares MV, Battistini L, Akbar AN. Reversible senescence in human CD4+CD45RA+CD27- memory T cells. *J Immunol*. 2011 Sep 1;187(5):2093-100. doi: 10.4049/jimmunol.1100978. Epub 2011 Jul 25. PubMed PMID: 21788446. Cit: 93. IF: 5.185
- 13: Libri V, Azevedo RI, Jackson SE, Di Mitri D, Lachmann R, Fuhrmann S, Vukmanovic-Stejic M, Yong K, Battistini L, Kern F, Soares MV, Akbar AN. Cytomegalovirus infection induces the accumulation of short-lived, multifunctional CD4+CD45RA+CD27+ T cells: the potential involvement of interleukin-7 in this process. *Immunology*. 2011 Mar;132(3):326-39. doi: 10.1111/j.1365-2567.2010.03386.x. Epub 2011 Jan 7. PubMed PMID: 21214539; PubMed Central PMCID: PMC3044899. Cit: 58. IF: 3.358
- 14: Fiorenzo P, Mongiardi MP, Dimitri D, Cozzolino M, Ferri A, Montano N, Trevisi G, Maira G, Battistini L, Falchetti ML, Levi A, Pallini R. HIF1-positive and HIF1-negative glioblastoma cells compete in vitro but cooperate in tumor growth in vivo. *Int J Oncol*. 2010 Apr;36(4):785-91. PMID: 2019832014. Cit: 18. IF: 3.079
- 15: Di Mitri D, Dalla Libera D, Bergami A, Centonze D, Gasperini C, Grasso MG, Galgani S, Martinelli V, Comi G, Avolio C, Martino G, Borsellino G, Sallusto F, Battistini L, Furlan R. T regulatory cells are markers of disease activity in multiple sclerosis patients. *PLoS One*. 2011;6(6):e21386. doi: 10.1371/journal.pone.0021386. Epub 2011 Jun 24. PubMed PMID: 21731726; PubMed Central PMCID: PMC3123332. Cit: 32. IF: 2.806
- 16: Chiacchio T, Casetti R, Butera O, Vanini V, Carrara S, Girardi E, Di Mitri D, Battistini L, Martini F, Borsellino G, Goletti D. Characterization of regulatory T cells identified as CD4(+)/CD25(high)/CD39(+) in patients with active tuberculosis. *Clin Exp Immunol*. 2009 Jun;156(3):463-70. doi: 10.1111/j.1365-2249.2009.03908.x. PubMed PMID: 19438599; PubMed Central PMCID: PMC2691975. Cit: 49. IF: 3.41
- 17: Kleinewietfeld M, Starke M, Di Mitri D, Borsellino G, Battistini L, Röttschke O, Falk K. CD49d provides access to "untouched" human Foxp3+ Treg free of contaminating effector cells. *Blood*. 2009 Jan 22;113(4):827-36. doi: 10.1182/blood-2008-04-150524. Epub 2008 Oct 21. PubMed PMID: 18941119. Cit: 92. IF: 13.164

18: Campo S, Arseni B, Rossi S, D'Alessio V, Lu R, Ngoje J, Ahl PL, Bonitz S, Mannino R, Di Mitri D, Battistini L, Carminati P, De Santis R, Ruggiero V. Efficacy of a nanochleate-encapsulated 3,5-diaryl-s-triazole derivative in a murine model of graft-versus-host disease. Transplantation. 2008 Jul 15;86(1):171-5. doi: 10.1097/TP.0b013e31817ba761. PubMed PMID: 18622296. Cit: 6. IF: 3.678

Place and date

Guanzate, 27/08/2018



Diletta Di Mitri